卡波扎尼布
甲状腺髓样癌
肾细胞癌
医学
甲状腺癌
机制(生物学)
动作(物理)
药代动力学
甲状腺癌
作用机理
癌症
药理学
重症监护医学
计算机科学
甲状腺
肿瘤科
化学
内科学
体外
哲学
物理
认识论
量子力学
生物化学
作者
AKANKSHA DWIVEDI,RAKHI KHABIYA,Alankar Shrivastava,SIDDHARTH TYAGI,KANDASAMY NAGARAJAN,G. N. Darwhekar
标识
DOI:10.22159/ijap.2023v15i1.46409
摘要
Globally, the burden of cancer is substantial and growing. The impact of the burden of such diseases over society is unpredictable in terms of health lost and cost. Unfortunately, the estimates shown the burden may be increasing in the upcoming decades. Cabozantinib (CBZ) is a newly developed tyrosin kinase inhibitor (TKI) for Differentiated thyroid cancer (DTC), Hepatic Cellular Carcinoma (HCC), Medullary thyroid cancer (MTC) and Renal Cell Carcinoma (RCC). The objective of the presented review is to provide updated knowledge of drugs especially covering analytical methodologies. The review covered the introduction, mechanism of action, pharmacokinetics, synthesis and developed analytical methods by various researchers. The review covered one spectrophotometry and about twenty chromatography methods. The review will be helpful for the scientist working in this area and especially helpful for analytical scientists exploring new analytical methodologies for CBZ.
科研通智能强力驱动
Strongly Powered by AbleSci AI